CLINICAL SIGNIFICANCE OF GENE CYP2C19 POLYMORPHISM IN STEMI PATIENTS (DATA FROM THE KEMEROVO REGISTRY OF THE ACUTE CORONARY SYNDROME)

A.M. Kochergina (1), V.V. Kashtalap (1, 2), L.A. Gordeeva (3), N.A. Kochergin (1), O.L. Barbarash (1 , 2)
1-State Research Institute for Complex Issues of Cardiovascular Diseases under the Siberian Branch of the Russian Academy
of Medical Sciences, Sosnovyi boul., 6, Kemerovo, 650000, Russian Federation;
2-Kemerovo State Medical University, Voroshilova street, 22 A, Kemerovo, 650070, Russian Federation;
3-State Research Institute of Human Ecology, Leningradskiy prospect, 10, Kemerovo, 650065, Russian Federation
E-mail: noony88@mail.ru

Aim is to evaluate distribution and clinical significance of gene CYP2C19 polymorfism in ST-segment elevation myocardial infarction (STEMI) patients. Materials and methods. A total of 159 patients were encluded in this study. All of them underwent primary PCI. According to CYP2C19 inheritance, patients were divided into two groups: «poor» metabolizers and «normal» metabolizers. Results. Poor metabolizing genotype was found in 20 patients (12,57%): CYP2C19*2 (rs4244285) – in 18 cases, а CYP2C19 *3 (rs4986893) – in 2 cases. Both groups were matched by age, gender, diabetes, active smoking. Hospital mortality rate was the same in both groups. Stent thrombosis occurred in patient with normal metabolizers subgroup. Conclusion. The accepted data give no insurance that both resistance clopidogrel is widely spread among STEMI patients in Kemerovo and it provides any clinical impact on STEMI complications and outcomes. Allele CYP2C19 * 3 is the most widely distributed among people of Asian descent, therefore, in the sample presented by Caucasians, this allele is expected to occur extremely rare
Keywords: 
pharmacogenetics; clopidogrel; myocardial infarction